Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Dendreon Corporation    

 SummaryNewsCalendarCompanyFinancials 
Company
Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer.The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a... 
Sector
Biotechnology & Medical Research
Calendar

- No events available -

More about the company
Latest news on DENDREON CORPORATION
2015DJValeant Approved to Buy Dendreon Assets for $495 Million
2015 Drugmaker Valeant close to buying Salix - source
2015 VALEANT SECURES FINANCING FOR POTENT : Bloomberg
2015DJEnergy Future Fights for Control of its Bankruptcy -- Week Ahead
2015 DENDREON : Valeant to buy Dendreon's prostate cancer vaccine Provenge
2014 DENDREON CORPORATION : A New Combined Approach to Cancer Immunotherapy is Needed
2014 DENDREON CORPORATION : Bankruptcies, Breakouts, and Busts; What's Happening in B..
2014DJMARKET SNAPSHOT : U.S. Stocks Eke Out Monday Gains; S&P 500, Dow Hit Records
2014DJMARKET SNAPSHOT : U.S. Stocks Eke Out Monday Gains; S&P 500, Dow Hit Records
2014DJMARKET SNAPSHOT : U.S. Stocks Eke Out Monday Gains; S&P 500, Dow Hit Records
More news
Sector news : Biotechnology & Medical Research - NEC
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
09/07 New AstraZeneca, Amgen drug looks strong rival in severe asthma
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag -- Update
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag
08/29DJGILEAD SCIENCES : Bets $11 Billion On New Cancer Therapy -- WSJ
More sector news : Biotechnology & Medical Research - NEC
Income Statement Evolution
Managers
NameTitle
Craig R. Jalbert President, Secretary, Treasurer & Director
William Monteith Executive Vice President-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
DENDREON CORPORATION0
INCYTE CORPORATION18.83%24 941
QUINTILES IMS HOLDINGS INC24.22%20 585
LONZA GROUP54.86%19 540
CELLTRION, INC.--.--%15 038
ALKERMES PLC-6.41%7 993